SOURCE: Leerink Swann & Co.

March 02, 2006 08:54 ET

Leerink Swann & Company Initiates Coverage of Watson Pharmaceuticals, Inc. (NYSE: WPI)

BOSTON, MA -- (MARKET WIRE) -- March 2, 2006 -- This morning, Senior Generic Pharmaceuticals Analyst, William F. Sawyer, initiated coverage of Watson Pharmaceuticals, Inc. (NYSE: WPI) with an Outperform rating based on his view that increased generic launch activity, coupled with ongoing cost control initiatives, could drive solid operating results in 2007 and beyond. Furthermore, he believes patent challenge wins and/or litigation settlements could drive upside to current estimates.

About Watson Pharmaceuticals, Inc. (NYSE: WPI)

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. The company is headquartered in Corona, California.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2005 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. Through its internal team of experts and its dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564